期刊
JOURNAL OF ONCOLOGY
卷 2022, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2022/4330329
关键词
-
类别
资金
- Training Program for the Youth Talent of the Changzhou Commission of Health [CZQM2020016]
- Natural Science Foundation of Jiangsu Province [BK20211065]
CD73 is a promising immunotherapy target in GI cancer, and combining it with other therapies can improve prognosis and survival rate.
Gastrointestinal (GI) cancer is a common and deadly malignant tumor. CD73, a cell-surface protein, acts as a switch of the adenosine-related signaling pathway that can cause significant immunosuppression. Recent evidence has emerged that CD73 is a promising immunotherapy target for regaining immune cell function and restraining tumorigenesis, and a growing stream of research indicates that combining immunotherapy with other therapies can effectively improve the prognosis and survival of GI cancer patients. Several immune checkpoint inhibitors have been approved for use in GI cancer recently; however, they have demonstrated limited efficacy. Solving the problem of immunosuppression in GI cancer is the key to developing an effective therapeutic option and the modulation of CD73 expression may provide an answer. In this review, we discuss current research on CD73 in gastric, liver, pancreatic, and colorectal cancer to evaluate its therapeutic potential as an immunotherapy target in GI cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据